The New England Chapter of the PDA

Workshop on Development and Commercialization of Combination Products
Commercialization of an Iontophoretic Drug Delivery System

Presented by:
George M. Baskinger
Associate Director, Regulatory Affairs
Vyteris, Inc.
The Drug Device Combination Product
Background

- The LidoSite™ product
  - a local anesthetic for topical use
  - a drug/device combination
  - primary mode of action is pharmaceutical
  - jurisdiction assigned to CDER’s Division of Anesthetic, Critical Care, and Addictive Drug Products
  - a collaboration with CDRH’s Division of General, Restorative and Neurological Devices
Regulatory Plan

- Submissions
  - an “umbrella” IND for the development of the Iontophoretic patch
  - a New Drug Application for the patch
  - a 510(k) for the controller

- Ombudsman
  - Requested help to facilitate communication between CDER and CDRH
Commercialization

- Quality System
- Scale Up
- Validation
- Marketing and Distribution
- Reporting
- Labeling
- Registrations and Listings
Quality System

- Drug cGMP vs QSR
  - Controller was designed and developed under QSR Design Controls
  - Patch developed with the pharmaceutical development report approach
  - Quality System was a hybrid system to accommodate both regulations (21CFR210, 211 and 820)
Scale Up

- Patch Manufacturing
  - Solution manufacturing (2)
    - Anode (drug) and cathode
  - Patch fabrication
  - Patch pouching
  - Packaging/Labeling

- Device Manufacturing
  - Outsourced to a contract manufacturer
Validation

- Validation (IQ/OQ/PQ)
  - Facility (HVAC, water, etc.)
  - Equipment
  - Process
  - Computer
  - Analytical and Physical Test Methods
  - Documentation/training
Marketing and Distribution

- Patch and Controller sold separately
  - Patch - single use disposable
  - Controller – multiple use
- Licensed to B. Braun
  - Product Samples
  - Demonstration product
- Advertised as a system
Reporting

- Post marketing Requirements
  - Drug
    - Field Alert Report
    - Periodic Safety Reports
      - 15 day “alert reports” MedWatch FDA Form 3500A
      - quarterly reports
    - Annual Report
  - Device
    - 5 day Reports
    - Baseline Report
    - Annual Report
Labeling

■ Product
  ■ Carton and container labels
  ■ Package Insert/Instructions for Use
    ■ PI/IFU covered both the patch and controller
    ■ Negotiated the “indications for use”

■ Other
  ■ Advertising and Promotional Material
    ■ Submitted to DDMAC
Registrations and Listings

- Drug Product Listing-Form FDA 2657
- Drug Establishment/Labeler Code-Form FDA 2656
- Medical Device Listing-Form FDA 2892
- Device Establishment Registration-Form FDA 2891 - (initial)